Current Report Filing (8-k)
April 17 2018 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 17, 2018
SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-30171
|
|
68-0359556
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
501 Canal Blvd., Richmond, California 94804
(Address of principal executive offices) (Zip Code)
(510)
970-6000
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former Address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On April 17, 2018, Sangamo Therapeutics, Inc. (the Company) announced a
data security incident involving the compromise of a senior executives Company email account. Upon learning of the incident on March 28, 2018, external network security experts were promptly engaged, and the incident response team worked
diligently to investigate the incident. The Company also promptly notified federal law enforcement of the incident. The investigation concluded that the incident was limited to the compromise of the senior executives Company email account for
approximately 11 weeks. The investigation did not reveal any evidence that the Companys network or other information technology systems were otherwise compromised in connection with the incident or that the incident resulted in the disclosure
of or access to personal information about patients or other individuals besides the holder of the Company email account that was affected. However, proprietary, confidential and other sensitive information of the Company and other entities was
accessed and may have been compromised as a result of the incident. The Company is continuing to analyze the effects of the incident, along with appropriate remediation of the Companys information technology systems, and that analysis and the
related remediation efforts could ultimately reveal that other Company information technology systems were compromised and/or that additional information was revealed or compromised.
In connection with the data security incident, the Company is also filing information for the purpose of supplementing and updating the risk factor
disclosures contained in its prior public filings, including those discussed under the heading Item 1A. Risk Factors in the Companys Annual Report on
Form 10-K for
the year ended
December 31, 2017, filed with the SEC on March 1, 2018. The updated risk factor disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
DATE: April 17, 2018
|
|
|
SANGAMO THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ HEATHER TURNER
|
|
|
Heather Turner
|
|
|
Senior Vice President and General Counsel
|
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024